May 20, 2025 · Ninlaro is a cancer medicine used to treat multiple myeloma (bone marrow cancer), in combination chemotherapy with lenalidomide and dexamethasone.

NINLARO is the first and only oral medication of its kind, a proteasome inhibitor, that may help people when their multiple myeloma comes back. In a study of multiple myeloma patients whose disease …

Oct 6, 2024 · Find patient medical information for Ninlaro (ixazomib) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings

NINLARO in combination with lenalidomide and dexamethasone is an approved treatment for relapsed multiple myeloma after at least 1 previous therapy, including indolent relapsed multiple myeloma. …

Aug 18, 2025 · 2.1 Dosing and Administration Guidelines - NINLARO in combination with lenalidomide and dexamethasone - The recommended starting dose of NINLARO is 4 mg administered orally …

The requested medication is prescribed in combination with pomalidomide and dexamethasone for patients who have received at least two prior therapies including an immunomodulatory agent and a …

Aug 1, 2024 · Ninlaro (Ixazomib Capsules) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.

4 days ago · The all-oral NINLARO treatment combination gives time back to you as well as your loved ones and care partners. With no travel to the clinic required for dosing of the all-oral NINLARO …

Apr 25, 2017 · Ninlaro (ixazomib citrate) is a proteasome inhibitor used to treat patients with multiple myleoma. Multiple myeloma is a type of cancer of the bone marrow, which occurs when plasma cells …

May 23, 2024 · The doctor will give the patient medication to help prevent nausea and vomiting before each dose of Ninlaro. Precautions should be taken to prevent dehydration caused by vomiting. The …